Alzheimer’s Disease/Dementia News

Treatment with non-invasive, personalized repetitive transcranial magnetic stimulation in those with mild to moderate Alzheimer’s resulted in a 44% slowing of disease progression at 52 weeks, according to the manufacturer.

Cardiovascular health of middle-aged adults was significantly associated with the risk of poor brain health later in life, according to a study published in Neurology.

In patients with type 2 diabetes, semaglutide was associated with a significantly lower risk for an Alzheimer’s disease diagnosis within 3 years compared with other diabetes medications, according to a study published in Alzheimer’s & Dementia.

BOSTON — In this Healio video exclusive, Virend K. Somers, MD, PhD, discusses his presentation at the Cardiometabolic Health Congress, “Sleep Disorders and Cardiometabolic Health.”

A genetic analysis of postmortem brains from individuals in various stages of Alzheimer’s disease revealed two distinct phases of cell deterioration, according to research published in Nature Neuroscience.

The NIH has awarded a $3.3 million grant to advance a novel, oral silent allosteric modulator intended to treat Alzheimer’s and Parkinson’s diseases, according to the manufacturer.

Falling was associated with an increased risk for a diagnosis of Alzheimer’s disease or other dementias in older adults, according to a recent analysis in JAMA Network Open.

The world is facing an impending tsunami as the number of people developing Alzheimer’s disease continues to grow.

A New York-based biotechnology company has received a $4 million grant from the NIH’s National Institute on Aging to advance a novel intranasal therapeutic to treat Alzheimer’s disease, according to a press release from the manufacturer.

ORLANDO, Fla. — An analysis of a large cohort of individuals enrolled in a continuous, multinational survey found no clear associations between brain and heart health and pet ownership, according to a poster.